

# Supplementary Documents [IFRS]

Financial results for the fiscal year 2020 (FY2020)

## Astellas Pharma Inc.

- FY2020 Financial Results
  - For the year ended March 31, 2021
  - Three months ended March 31, 2021
- Pipeline list

### Cautionary Notes

*In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.*

## [For the year ended March 31, 2021]

### 1. Consolidated Results (Full Basis)

	Unit: B¥				Forecasts		Change from FY20	
	FY19 Full Year	FY20 Full Year	Change	Change (%)	FY20 Full Year	FY21 Full Year	Change (%)	
Revenue	1,300.8	1,249.5	-51.3	-3.9%	1,256.5	1,323.0	5.9%	
Cost of sales	276.7	246.1	-30.7	-11.1%				
Ratio to Revenue	21.3%	19.7%						
Gross profit	1,024.1	1,003.5	-20.6	-2.0%				
SG&A expenses	499.3	504.3	5.0	1.0%		541.0	7.3%	
Ratio to Revenue	38.4%	40.4%				40.9%		
Advertising and Sales Promotion	172.4	180.7	8.3	4.8%				
Personnel expenses	179.8	182.2	2.4	1.3%				
Other	147.0	141.4	-5.6	-3.8%				
R&D expenses	224.2	224.5	0.3	0.1%	233.5	242.0	7.8%	
Ratio to Revenue	17.2%	18.0%			18.6%	18.3%		
Amortisation of intangible assets	21.2	23.8	2.6	12.3%				
Share of profit (loss) of investments accounted for using equity method	-1.7	0.5	2.1	-				
Other income	12.2	7.6	-4.5	-37.2%				
Gain on sales of property, plant and equipment	3.9	0.0	-3.9	-99.4%				
Fair value remeasurements on contingent consideration	0.4	3.6	3.2	738.0%				
Other expense	45.9	123.0	77.0	167.8%				
Impairment losses	13.8	101.7	88.0	637.5%				
Restructuring costs	1.8	9.3	7.5	408.0%				
Net foreign exchange losses	8.9	2.3	-6.6	-73.9%				
Fair value remeasurements on contingent consideration	11.2	6.0	-5.2	-46.3%				
Operating profit	244.0	136.1	-107.9	-44.2%	210.5	265.0	94.8%	
Ratio to Revenue	18.8%	10.9%			16.8%	20.0%		
Finance income	4.4	11.6	7.2	166.0%				
Finance expense	3.0	2.3	-0.7	-22.3%				
Profit before tax	245.4	145.3	-100.0	-40.8%	209.5	263.0	81.0%	
Ratio to Revenue	18.9%	11.6%			16.7%	19.9%		
Income tax expense	49.9	24.7	-25.2	-50.5%				
Profit	195.4	120.6	-74.8	-38.3%	169.5	209.0	73.3%	
Ratio to Revenue	15.0%	9.7%			13.5%	15.8%		
Comprehensive income	156.7	181.5	24.8	15.8%				

## 2. Consolidated Results (Core Basis)

Unit: B¥

	FY19 Full Year	FY20 Full Year	Change	Change (%)
Revenue	1,300.8	1,249.5	-51.3	-3.9%
Cost of sales	276.7	246.1	-30.7	-11.1%
Ratio to Revenue	21.3%	19.7%		
Gross profit	1,024.1	1,003.5	-20.6	-2.0%
SG&A expenses	499.3	504.3	5.0	1.0%
Ratio to Revenue	38.4%	40.4%		
Advertising and Sales Promotion	172.4	180.7	8.3	4.8%
Personnel expenses	179.8	182.2	2.4	1.3%
Other	147.0	141.4	-5.6	-3.8%
R&D expenses	224.2	224.5	0.3	0.1%
Ratio to Revenue	17.2%	18.0%		
Amortisation of intangible assets	21.2	23.8	2.6	12.3%
Share of profit (loss) of investments accounted for using equity method	-1.7	0.5	2.1	-
Operating profit	277.8	251.4	-26.4	-9.5%
Ratio to Revenue	21.4%	20.1%		
Finance income	4.4	11.6	7.2	166.0%
Finance expense	3.0	2.3	-0.7	-22.3%
Profit before tax	279.1	260.6	-18.5	-6.6%
Ratio to Revenue	21.5%	20.9%		
Income tax expense	55.9	50.7	-5.2	-9.3%
Profit	223.2	209.9	-13.3	-5.9%
Ratio to Revenue	17.2%	16.8%		

Forecasts

FY20 Full Year
1,256.5
233.5
18.6%
251.0
20.0%
200.5
16.0%

Change from  
FY20

Forecasts FY21 Full Year	Change (%)
1,323.0	5.9%
541.0	7.3%
40.9%	
242.0	7.8%
18.3%	
270.0	7.4%
20.4%	
213.0	1.5%
16.1%	

## 3. Exchange Rate

Unit: yen

	FY19 Ave.	FY20 Ave.	FY19 End	FY20 End
USD/Yen	109	106	109	111
EUR/Yen	121	124	120	130

Forecasts

FY20 Full Year
109
120

Forecasts

FY21 Full Year
110
130

\* Fx impacts: Revenue -4.6 billion yen and Core operating profit -7.3 billion yen

\* Fx impact on elimination of unrealized gain: COGs ratio +0.8ppt

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY19 Full year			FY20 Full year		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
<b>Revenue</b>	<b>1,300.8</b>	-	<b>1,300.8</b>	<b>1,249.5</b>	-	<b>1,249.5</b>
Cost of sales	276.7	-	276.7	246.1	-	246.1
<b>Gross profit</b>	<b>1,024.1</b>	-	<b>1,024.1</b>	<b>1,003.5</b>	-	<b>1,003.5</b>
SG&A expenses	499.3	-	499.3	504.3	-	504.3
R&D expenses	224.2	-	224.2	224.5	-	224.5
Amortisation of intangible assets	21.2	-	21.2	23.8	-	23.8
Share of profit (loss) of investments accounted	-1.7	-	-1.7	0.5	-	0.5
Other income *	12.2	-12.2	-	7.6	-7.6	-
Other expenses *	45.9	-45.9	-	123.0	-123.0	-
<b>Operating profit</b>	<b>244.0</b>	<b>33.8</b>	<b>277.8</b>	<b>136.1</b>	<b>115.3</b>	<b>251.4</b>
Finance income	4.4	-	4.4	11.6	-	11.6
Finance expenses	3.0	-	3.0	2.3	-	2.3
<b>Profit before tax</b>	<b>245.4</b>	<b>33.8</b>	<b>279.1</b>	<b>145.3</b>	<b>115.3</b>	<b>260.6</b>
Income tax expense	49.9	6.0	55.9	24.7	26.0	50.7
<b>Profit</b>	<b>195.4</b>	<b>27.8</b>	<b>223.2</b>	<b>120.6</b>	<b>89.3</b>	<b>209.9</b>

\* "Other income" and "Other expenses" are excluded from Full basis results.

"Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

## 5. Revenue by Region

		Unit: B¥				Forecasts		Change from FY20	
		FY19 Full Year	FY20 Full Year	Change	Change (%)	FY20 Full Year	FY21 Full Year	Change (%)	
Revenue		1,300.8	1,249.5	-51.3	-3.9%	1,256.5	1,323.0	5.9%	
	Japan	345.4	279.1	-66.3	-19.2%	281.7	249.8	-10.5%	
	Ratio to Revenue	26.6%	22.3%			22.4%	18.9%		
	United States	443.5	473.2	29.7	6.7%	486.4	544.6	15.1%	
	Ratio to Revenue	34.1%	37.9%			38.7%	41.2%		
	Established Markets	296.1	293.2	-2.9	-1.0%	287.5	331.9	13.2%	
	Ratio to Revenue	22.8%	23.5%			22.9%	25.1%		
	Greater China	60.4	59.3	-1.1	-1.8%	67.2	63.8	7.7%	
	Ratio to Revenue	4.6%	4.7%			5.4%	4.8%		
	International Markets	134.8	111.1	-23.7	-17.6%	117.1	122.7	10.4%	
	Ratio to Revenue	10.4%	8.9%			9.3%	9.3%		
	Others	20.7	33.6	12.9	62.3%	16.5	10.1	-70.1%	
	Ratio to Revenue	1.6%	2.7%			1.3%	0.8%		

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

## 6. Per Share Information

	FY19 Full Year	FY20 Full Year	Forecasts FY20 Full Year	Forecasts FY21 Full Year
The number of shares issued (thousand)	1,861,787	1,861,787		
Treasury Shares (thousand)	4,276	8,758		
The number of shares issued after deducting Treasury Shares (thousand)	1,857,511	1,853,029		
Earnings per share (yen)	104.15	64.93	91.25	112.79
Earnings per share (yen) core base	118.95	113.03	107.94	114.95
Dividend per share (yen)	40	42	42	50
Return on Equity (%)	15.3%	9.0%		
Dividend on Earnings (%)	5.9%	5.8%		

## 7. Addition to Property, Plant and Equipment

### Depreciation/Amortisation

		Unit: B¥				Forecasts		Change from FY20	
		FY19 Full Year	FY20 Full Year	Change	Change (%)	FY20 Full Year	FY21 Full Year	Change (%)	
Addition to Property, Plant and Equipment									
	Consolidated	41.8	33.7	-8.1	-19.3%	29.0	36.0	6.8%	
Depreciation (PP&E)									
	Consolidated	37.5	40.0	2.5	6.6%	41.0	43.0	7.5%	
Amortisation of Intangible Assets (incl. software, etc.)									
	Consolidated	28.9	32.7	3.8	13.1%	30.0	39.0	19.4%	

- Addition to Property, Plant and Equipment does not include right-of-use asset.

8. Sales of major products

1) Global

	Unit: B¥				Forecasts		Change from FY20	
	FY19 Full Year	FY20 Full Year	Change	Change (%)	FY20 Full Year	FY21 Full Year	Change (%)	
XTANDI	400.0	458.4	58.4	14.6%	464.6	557.2	21.5%	
United States	203.5	238.6	35.1	17.3%	249.5	288.0	20.7%	
ex-US	196.5	219.8	23.3	11.9%	215.1	269.2	22.5%	
Japan	35.8	40.2	4.4	12.4%	38.9	45.4	12.8%	
Established Markets	135.4	149.3	13.8	10.2%	142.9	183.0	22.6%	
Greater China	3.2	4.9	1.7	52.8%	6.9	7.0	43.6%	
International Markets	22.1	25.5	3.4	15.2%	26.4	33.8	32.7%	
XOSPATA	14.3	23.8	9.6	67.2%	23.1	36.7	53.8%	
Japan	2.8	3.8	1.0	35.4%	3.2	4.4	16.0%	
United States	10.5	15.5	5.0	47.0%	13.8	20.0	29.3%	
Established Markets	0.9	4.4	3.5	370.5%	5.5	9.8	123.2%	
Greater China	-	0.0	0.0	-	-	1.6	-	
International Markets	-	0.2	0.2	-	-	0.9	488.4%	
PADCEV	1.8	12.8	11.0	607.3%	13.0	20.1	57.1%	
United States	1.8	12.8	11.0	607.3%	13.0	19.1	49.3%	
Evrenzo	0.2	1.1	0.9	371.2%	-	8.6	661.0%	
Japan	0.2	1.1	0.9	371.2%	-	4.1	262.8%	
Betanis/Myrabetriq/BETMIGA	161.6	163.6	2.0	1.2%	167.9	175.2	7.1%	
Japan	34.3	35.1	0.7	2.1%	34.2	35.8	2.2%	
United States	89.2	88.0	-1.3	-1.4%	90.8	94.2	7.0%	
Established Markets	28.2	29.9	1.7	6.0%	30.5	35.6	19.1%	
Greater China	1.4	2.2	0.8	59.3%	3.1	2.5	15.0%	
International Markets	8.4	8.5	0.1	0.8%	9.3	7.1	-15.9%	
Vesicare	44.7	31.6	-13.1	-29.3%	30.0	16.1	-49.2%	
Japan	20.2	18.5	-1.7	-8.4%	17.1	5.5	-70.4%	
United States	5.4	2.2	-3.3	-60.1%	2.2	1.2	-43.3%	
Established Markets	13.1	6.2	-6.8	-52.4%	5.2	4.9	-21.5%	
Greater China	1.8	1.0	-0.8	-44.6%	1.2	0.8	-23.4%	
International Markets	4.2	3.7	-0.4	-10.6%	4.3	3.7	-1.1%	
Prograf	192.9	182.7	-10.3	-5.3%	182.0	192.6	5.5%	
Japan	44.3	40.7	-3.6	-8.1%	40.5	38.5	-5.5%	
United States	13.2	11.8	-1.4	-10.5%	12.1	11.1	-6.1%	
Established Markets	71.5	64.2	-7.3	-10.3%	62.6	69.8	8.8%	
Greater China	32.2	34.2	2.0	6.2%	35.1	37.1	8.4%	
International Markets	31.7	31.7	0.0	0.1%	31.6	36.2	14.1%	
Harnal/Omnice	42.7	36.9	-5.7	-13.5%	39.1	34.3	-7.1%	
Funguard/MYCAMINE	35.2	25.6	-9.6	-27.3%	23.1	14.7	-42.5%	
Eligard	14.2	9.5	-4.8	-33.4%	12.3	-	-	

- Sales of products in Japan are shown in a gross sales basis

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

2) Revenue by region

(1) Japan

Unit: B¥

<Global>	FY19 Full Year	FY20 Full Year	Change	Change (%)
XTANDI	35.8	40.2	4.4	12.4%
XOSPATA	2.8	3.8	1.0	35.4%
Evrenzo	0.2	1.1	0.9	371.2%
Betanis	34.3	35.1	0.7	2.1%
Vesicare	20.2	18.5	-1.7	-8.4%
Prograf (Including Gracaptor)	44.3	40.7	-3.6	-8.1%
Harnal	4.1	3.0	-1.1	-27.1%
Funguard	7.6	4.4	-3.1	-41.6%

Forecasts	Forecasts	Change from FY20
FY20 Full Year	FY21 Full Year	Change (%)
38.9	45.4	12.8%
3.2	4.4	16.0%
	4.1	262.8%
34.2	35.8	2.2%
17.1	5.5	-70.4%
40.5	38.5	-5.5%
2.6	2.1	-28.9%
3.6	1.8	-58.3%

<Main products>

Suglat [Family]	23.9	27.9	4.0	16.8%
Sujanu	8.9	11.3	2.4	26.8%
Repatha	3.1	5.1	2.0	62.4%
Linzess	5.6	6.4	0.8	14.7%
BLINCYTO	4.5	4.5	0.1	1.4%
EVENITY	23.6	24.8	1.2	4.9%
Smyraf	0.3	1.7	1.4	463.9%
Celecox	49.2	18.9	-30.3	-61.6%
Symbicort	14.1	-	-14.1	-
Geninax	7.7	2.5	-5.2	-67.7%
Vaccines	11.2	7.9	-3.3	-29.4%
Gonax	5.1	5.1	-0.0	-0.5%
Cimzia	9.3	10.0	0.8	8.6%
Micardis [Family]	17.7	-	-17.7	-
Bonoteo	6.0	3.8	-2.2	-36.9%
Lipitor	12.7	10.6	-2.1	-16.5%
Myslee	9.0	7.8	-1.2	-13.4%
Total Rx Sales In Japanese market	342.1	276.6	-65.6	-19.2%

30.3	30.3	8.6%
6.6	6.9	7.9%
	3.1	89.5%
20.9		
-	-	-
5.0	4.5	79.8%
7.4	7.7	-3.2%
5.5	5.0	-1.7%
9.4		
-	-	-
3.2	2.9	-23.2%
10.2		
7.2	6.7	-15.0%
275.6	247.6	-10.5%

- Sales of products in Japan are shown in a gross sales basis.

## (2) United States

		Unit: M\$			
		FY19	FY20	Change	Change
		Full Year	Full Year		(%)
Revenue		4,078	4,462	383	9.4%
	XTANDI	1,871	2,250	379	20.2%
	XOSPATA	97	146	49	50.8%
	PADCEV	17	121	104	625.2%
	Myrbetriq	821	829	9	1.1%
	VESIcare	50	20	-30	-59.1%
	Prograf	122	112	-10	-8.2%
	MYCAMINE	106	83	-24	-22.4%
	AmBisome	116	114	-3	-2.3%
	CRESEMBA	155	160	5	3.0%
	Lexiscan	694	623	-71	-10.3%
	Tarceva	30	5	-25	-83.8%

		Forecasts		Change from
		FY20	FY21	FY20
		Full Year	Full Year	Change
				(%)
		4,446	4,951	11.0%
		2,280	2,618	16.4%
		126	182	24.6%
		119	174	43.9%
		830	856	3.2%
		20	11	-45.3%
		111	101	-9.5%
		62	17	-78.9%
		106	115	1.0%
		155	176	10.6%
		626	700	12.5%

## (3) Established Markets

		Unit: M€			
		FY19	FY20	Change	Change
		Full Year	Full Year		(%)
Revenue		2,451	2,370	-81	-3.3%
	XTANDI	1,121	1,207	86	7.6%
	XOSPATA	8	36	28	359.5%
	BETMIGA	233	241	8	3.5%
	Vesicare	108	50	-58	-53.5%
	Prograf	592	519	-73	-12.3%
	Omnic	71	65	-6	-9.0%
	MYCAMINE	56	45	-11	-20.1%
	Eligard	98	64	-33	-34.3%

		Forecasts		Change from
		FY20	FY21	FY20
		Full Year	Full Year	Change
				(%)
		2,403	2,553	7.7%
		1,195	1,408	16.7%
		46	75	112.3%
		255	274	13.3%
		43	38	-25.3%
		524	537	3.5%
		63	63	-3.7%
		40	22	-51.2%
		81	-	-

- Established Markets: Europe, Canada, Australia



## (4) Greater China

Unit: B¥

	FY19 Full Year	FY20 Full Year	Change	Change (%)
Revenue	60.4	59.3	-1.1	-1.8%
XTANDI	3.2	4.9	1.7	52.8%
XOSPATA	-	0.0	0.0	-
BETMIGA	1.4	2.2	0.8	59.3%
Vesicare	1.8	1.0	-0.8	-44.6%
Prograf	32.2	34.2	2.0	6.2%
Harnal	13.1	10.8	-2.2	-17.1%
MYCAMINE	3.8	2.5	-1.3	-34.3%
Eligard	0.3	0.3	0.0	2.9%
Feburic	2.5	2.6	0.1	4.5%

- Greater China: China, Hong Kong, Taiwan

Forecasts

Forecasts
FY20 Full Year
67.2
6.9
3.1
1.2
35.1
11.4
3.7
0.4
3.9

Change from  
FY20

Forecasts	Change from FY20
FY21 Full Year	Change (%)
63.8	7.7%
7.0	43.6%
1.6	-
2.5	15.0%
0.8	-23.4%
37.1	8.4%
8.0	-26.4%
3.4	37.7%
-	-
3.0	12.9%

## (5) International Markets

Unit: B¥

	FY19 Full Year	FY20 Full Year	Change	Change (%)
Revenue	134.8	111.1	-23.7	-17.6%
XTANDI	22.1	25.5	3.4	15.2%
XOSPATA	-	0.2	0.2	-
BETMIGA	8.4	8.5	0.1	0.8%
Vesicare	4.2	3.7	-0.4	-10.6%
Prograf	31.7	31.7	0.0	0.1%
Harnal	16.9	15.1	-1.8	-10.7%
MYCAMINE	5.5	4.4	-1.1	-20.2%

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

Forecasts

Forecasts
FY20 Full Year
117.1
26.4
9.3
4.3
31.6
17.6
4.2

Change from  
FY20

Forecasts	Change from FY20
FY21 Full Year	Change (%)
122.7	10.4%
33.8	32.7%
0.9	488.4%
7.1	-15.9%
3.7	-1.1%
36.2	14.1%
16.1	6.6%
4.7	7.3%

## 9. Consolidated statements of financial position

Unit: B¥

	FY19 End	FY20 End	Change
<b>Assets</b>	<b>2,315.2</b>	<b>2,273.6</b>	<b>-41.5</b>
<b>Non-current assets</b>	<b>1,447.7</b>	<b>1,401.0</b>	<b>-46.6</b>
Property, plant and equipment	268.6	264.6	-4.0
Goodwill	278.3	284.0	5.8
Intangible assets	724.8	651.4	-73.3
Trade and other receivables	34.0	33.9	-0.1
Investments accounted for using equity method	4.7	7.1	2.4
Deferred tax assets	52.9	54.2	1.3
Other financial assets	74.3	95.9	21.6
Other non-current assets	10.2	9.9	-0.3
<b>Current assets</b>	<b>867.5</b>	<b>872.6</b>	<b>5.1</b>
Inventories	151.0	164.1	13.1
Trade and other receivables	347.0	343.2	-3.9
Income tax receivable	23.6	14.0	-9.6
Other financial assets	9.5	5.6	-3.9
Other current assets	18.0	19.7	1.6
Cash and cash equivalents	318.4	326.1	7.7

Unit: B¥

	FY19 End	FY20 End	Change
<b>Equity and Liabilities</b>	<b>2,315.2</b>	<b>2,273.6</b>	<b>-41.5</b>
<b>Equity</b>	<b>1,289.2</b>	<b>1,386.1</b>	<b>96.9</b>
<b>Equity attributable to owners of the parent</b>	<b>1,289.2</b>	<b>1,386.1</b>	<b>96.9</b>
Share capital	103.0	103.0	-
Capital surplus	177.5	177.8	0.3
Treasury shares	-7.2	-15.4	-8.2
Retained earnings	905.9	953.3	47.4
Other components of equity	110.0	167.4	57.4
<b>Liabilities</b>	<b>1,026.0</b>	<b>887.5</b>	<b>-138.5</b>
<b>Non-current liabilities</b>	<b>227.3</b>	<b>295.1</b>	<b>67.8</b>
Trade and other payables	3.1	0.4	-2.7
Deferred tax liabilities	24.7	18.2	-6.5
Retirement benefit liabilities	38.1	39.0	0.9
Provisions	6.1	5.8	-0.3
Other financial liabilities	129.3	199.0	69.7
Other non-current liabilities	26.0	32.8	6.8
<b>Current liabilities</b>	<b>798.7</b>	<b>592.4</b>	<b>-206.3</b>
Trade and other payables	172.0	124.8	-47.2
Income tax payable	4.0	8.4	4.4
Provisions	14.2	22.2	7.9
Other financial liabilities	345.7	148.2	-197.5
Other current liabilities	262.8	288.9	26.1

In the first three months of FY2020, the consolidated statement of financial position as of March 31, 2020 was retroactively revised due to adjustments of fair value of assets acquired and liabilities assumed for Audentes Therapeutics, Inc., which was acquired in January 2020. For the details, refer to Note "Business Combinations" in Financial Results.

10. Employees

Number of employees

	FY19 End	FY20 End
Total	15,883	15,455

11. Shareholders

	FY19 End	FY20 End
Banks	35.6%	38.3%
Securities	2.8%	4.3%
Other companies	3.2%	3.1%
Foreign companies	49.8%	45.6%
Individuals and others	8.6%	8.6%
Treasury Stock*	0.1%	0.1%

\* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust and ESOP (Employee Stock Ownership Plan) trust.

**[For the year ended March 31, 2021]**

1. Consolidated Results (Full Basis)

Unit: B¥

	FY20							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue	307.0	-8.1%	308.5	-2.5%	325.4	-3.7%	308.6	-1.2%
Cost of sales	59.7	-15.4%	59.9	-12.4%	68.2	-17.6%	58.3	5.9%
Ratio to Revenue	19.4%		19.4%		21.0%		18.9%	
Gross profit	247.3	-6.2%	248.6	0.3%	257.2	0.8%	250.3	-2.7%
SG&A expenses	120.8	2.8%	121.4	11.8%	120.9	-5.2%	141.3	-3.1%
Ratio to Revenue	39.3%		39.3%		37.2%		45.8%	
Advertising and Sales Promotion	42.0	1.8%	42.6	5.6%	43.2	-3.7%	52.9	15.1%
Personnel expenses	45.7	4.8%	44.6	4.2%	43.6	0.8%	48.3	-3.7%
Other	33.1	1.5%	34.2	34.2%	34.1	-13.4%	40.0	-19.3%
R&D expenses	57.3	7.1%	54.4	5.7%	57.1	4.3%	55.7	-13.7%
Ratio to Revenue	18.7%		17.6%		17.6%		18.0%	
Amortisation of intangible assets	5.9	-18.4%	5.7	41.6%	5.7	35.6%	6.5	13.0%
Share of profit (loss) of investments accounted for using equity method	-0.0	-	-0.2	-	0.0	-	0.7	43.5%
Other income	2.2	-50.4%	3.2	19.0%	3.9	-50.5%	2.7	14.2%
Fair value remeasurements on contingent consideration	0.9	-	3.1	-	0.0	-	-	-
Other expense	4.8	-60.6%	44.1	-	4.7	-	73.8	94.9%
Impairment losses	3.3	-	31.3	-	2.1	-	65.1	374.6%
Restructuring costs	-	-	0.9	-	1.9	-	6.4	252.2%
Net foreign exchange losses	-	-	6.4	-	-	-	-	-
Fair value remeasurements on contingent consideration	0.2	-98.5%	4.2	783.4%	0.2	275.4%	1.9	-
Operating profit	60.8	-21.1%	26.1	-69.4%	72.6	-3.8%	-23.4	-469.8%
Ratio to Revenue	19.8%		8.4%		22.3%		-7.6%	
Finance income	0.4	-50.5%	3.1	437.8%	3.1	22.6%	5.1	858.7%
Finance expense	1.0	-27.8%	0.3	-56.7%	0.5	46.5%	0.6	-16.0%
Profit before tax	60.2	-21.3%	28.9	-66.1%	75.1	-3.2%	-18.9	-406.6%
Ratio to Revenue	19.6%		9.4%		23.1%		-6.1%	
Income tax expense	9.8	-45.4%	6.4	-57.3%	15.1	-6.5%	-6.6	-948.3%
Profit	50.4	-13.9%	22.4	-68.0%	60.1	-2.3%	-12.3	-328.7%
Ratio to Revenue	16.4%		7.3%		18.5%		-4.0%	
Comprehensive income	55.4	104.9%	22.7	-52.3%	77.8	-18.8%	25.6	287.1%

## 2. Consolidated Results (Core Basis)

Unit: B¥

	FY20							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue	307.0	-8.1%	308.5	-2.5%	325.4	-3.7%	308.6	-1.2%
Cost of sales	59.7	-15.4%	59.9	-12.4%	68.2	-17.6%	58.3	5.9%
Ratio to Revenue	19.4%		19.4%		21.0%		18.9%	
Gross profit	247.3	-6.2%	248.6	0.3%	257.2	0.8%	250.3	-2.7%
SG&A expenses	120.8	2.8%	121.4	11.8%	120.9	-5.2%	141.3	-3.1%
Ratio to Revenue	39.3%		39.3%		37.2%		45.8%	
Advertising and Sales Promotion	42.0	1.8%	42.6	5.6%	43.2	-3.7%	52.9	15.1%
Personnel expenses	45.7	4.8%	44.6	4.2%	43.6	0.8%	48.3	-3.7%
Other	33.1	1.5%	34.2	34.2%	34.1	-13.4%	40.0	-19.3%
R&D expenses	57.3	7.1%	54.4	5.7%	57.1	4.3%	55.7	-13.7%
Ratio to Revenue	18.7%		17.6%		17.6%		18.0%	
Amortisation of intangible assets	5.9	-18.4%	5.7	41.6%	5.7	35.6%	6.5	13.0%
Share of profit (loss) of investments accounted for using equity method	-0.0	-	-0.2	-	0.0	-	0.7	43.5%
Operating profit	63.4	-25.2%	66.9	-19.6%	73.5	8.0%	47.6	13.9%
Ratio to Revenue	20.6%		21.7%		22.6%		15.4%	
Finance income	0.4	-50.5%	3.1	437.8%	3.1	22.6%	5.1	858.7%
Finance expense	1.0	-27.8%	0.3	-56.7%	0.5	46.5%	0.6	-16.0%
Profit before Tax	62.8	-25.4%	69.7	-16.2%	76.0	8.4%	52.1	25.2%
Ratio to Revenue	20.5%		22.6%		23.4%		16.9%	
Income tax expense	10.8	-36.7%	15.5	8.2%	15.5	9.4%	8.9	-13.9%
Profit	52.0	-22.5%	54.2	-21.3%	60.5	8.1%	43.3	38.1%
Ratio to Revenue	16.9%		17.6%		18.6%		14.0%	

### 3. Revenue by Region

Unit: B¥

		FY20							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue		307.0	-8.1%	308.5	-2.5%	325.4	-3.7%	308.6	-1.2%
	Japan	77.8	-21.0%	66.5	-21.7%	77.6	-16.5%	57.3	-17.2%
	Ratio to Revenue	25.3%		21.5%		23.8%		18.6%	
	United States	117.2	11.3%	119.6	7.3%	119.1	3.4%	117.4	5.2%
	Ratio to Revenue	38.2%		38.8%		36.6%		38.0%	
	Established Markets	64.0	-15.5%	74.8	5.4%	79.1	11.0%	75.2	-3.7%
	Ratio to Revenue	20.9%		24.3%		24.3%		24.4%	
	Greater China	14.2	-3.4%	15.3	4.4%	14.3	-4.5%	15.5	-3.4%
	Ratio to Revenue	4.6%		5.0%		4.4%		5.0%	
	International Markets	30.2	-11.8%	26.5	-8.9%	30.9	-21.8%	23.5	-26.4%
	Ratio to Revenue	9.8%		8.6%		9.5%		7.6%	
	Others	3.6	-36.4%	5.8	9.3%	4.6	3.1%	19.7	265.0%
	Ratio to Revenue	1.2%		1.9%		1.4%		6.4%	

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

### 4. Addition to Property, Plant and Equipment Depreciation/Amortisation

Unit: B¥

		FY20							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Addition to Property, Plant and Equipment									
	Consolidated	7.1	-43.8%	7.5	-24.2%	9.3	-1.3%	9.8	-0.2%
Depreciation (PP&E)									
	Consolidated	10.0	24.5%	10.0	20.8%	10.1	-9.2%	9.9	-1.9%
Amortisation of Intangible Assets (incl. software, etc.)									
	Consolidated	8.0	-10.9%	8.0	35.7%	8.1	33.5%	8.6	8.1%

- Addition to Property, Plant and Equipment does not include right-of-use asset.

5. Sales of major products

1) Global

Unit: B¥

		FY20							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI		112.0	16.6%	113.5	14.7%	117.2	13.9%	115.7	13.3%
	United States	62.7	33.7%	58.4	12.8%	58.9	10.7%	58.6	13.5%
	ex-US	49.3	0.3%	55.1	16.7%	58.3	17.3%	57.1	13.1%
	Japan	10.1	9.1%	9.8	4.0%	11.1	22.1%	9.2	15.1%
	Established Markets	31.5	-6.4%	37.4	15.1%	40.0	20.9%	40.5	11.5%
	Greater China	0.7	31.4%	1.6	219.0%	0.9	33.3%	1.7	14.4%
	International Markets	6.9	22.7%	6.4	32.3%	6.3	-8.0%	5.8	22.3%
XOSPATA		5.6	128.3%	5.3	64.4%	6.7	65.0%	6.2	37.8%
	Japan	1.0	70.3%	0.8	25.6%	1.1	17.6%	0.9	38.4%
	United States	3.6	92.3%	3.7	41.8%	4.3	43.0%	3.9	27.8%
	Established Markets	1.0	-	0.8	-	1.3	739.0%	1.2	60.4%
PADCEV		3.0	-	3.1	-	3.3	-	3.5	91.2%
	United States	3.0	-	3.1	-	3.3	-	3.5	91.2%
Evrenzo		0.2	-	0.2	-	0.4	119.6%	0.4	513.4%
	Japan	0.2	-	0.2	-	0.4	119.6%	0.4	513.4%
Betanis/Myrabetriq/BETMIGA		40.4	1.2%	39.5	1.8%	42.3	0.2%	41.3	1.8%
	Japan	8.4	-10.5%	8.2	-2.8%	10.0	4.0%	8.4	22.8%
	United States	22.9	7.7%	21.1	-0.3%	21.9	-4.9%	22.1	-7.2%
	Established Markets	6.6	-2.3%	7.7	12.4%	7.6	5.4%	7.9	8.2%
	Greater China	0.4	12.3%	0.5	79.8%	0.6	124.6%	0.6	44.9%
	International Markets	2.0	-2.5%	2.0	-3.9%	2.3	4.1%	2.2	5.2%
Vesicare		7.7	-43.0%	8.4	-26.5%	8.5	-23.6%	7.0	-18.7%
	Japan	4.9	-13.8%	4.4	-8.4%	5.2	-6.9%	3.9	-3.0%
	United States	0.4	85.7%	1.2	-51.4%	0.3	-82.6%	0.3	-73.3%
	Established Markets	1.3	-79.2%	1.6	-37.4%	1.7	-20.9%	1.6	-27.3%
	Greater China	0.2	-52.9%	0.3	-44.1%	0.3	-42.9%	0.3	-37.5%
	International Markets	0.9	-14.3%	0.9	-16.5%	1.0	-8.6%	0.9	-1.6%
Prograf		45.3	-10.2%	44.3	-3.2%	48.7	-2.6%	44.3	-5.1%
	Japan	11.1	-9.1%	10.0	-6.7%	11.1	-8.0%	8.6	-8.5%
	United States	3.6	10.1%	3.0	-21.0%	2.8	-27.3%	2.4	6.7%
	Established Markets	13.8	-21.9%	16.6	-0.5%	17.2	-0.2%	16.6	-16.8%
	Greater China	7.8	1.3%	8.4	7.9%	8.6	11.6%	9.4	4.4%
	International Markets	9.0	-6.0%	6.3	-7.0%	9.1	-1.4%	7.3	19.7%
Harnal/Omnic		10.6	-3.1%	9.6	-14.7%	8.7	-21.1%	8.0	-15.1%
Funguard/MYCAMINE		7.1	-21.6%	6.9	-21.4%	6.1	-35.6%	5.5	-30.4%
Eligard		3.1	-16.0%	3.1	-5.4%	3.2	-16.0%	0.1	-96.0%

- Sales of products in Japan are shown in a gross sales basis

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

2) Revenue by region

(1) Japan

Unit: B¥

<Global>	FY20							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI	10.1	9.1%	9.8	4.0%	11.1	22.1%	9.2	15.1%
XOSPATA	1.0	70.3%	0.8	25.6%	1.1	17.6%	0.9	38.4%
Evrenzo	0.2	-	0.2	-	0.4	119.6%	0.4	513.4%
Betanis	8.4	-10.5%	8.2	-2.8%	10.0	4.0%	8.4	22.8%
Vesicare	4.9	-13.8%	4.4	-8.4%	5.2	-6.9%	3.9	-3.0%
Prograf (Including Gracaptor)	11.1	-9.1%	10.0	-6.7%	11.1	-8.0%	8.6	-8.5%
Harnal	0.8	-30.5%	0.7	-28.0%	0.8	-24.6%	0.6	-24.0%
Funguard	1.5	-24.5%	1.4	-29.1%	1.1	-49.3%	0.4	-70.3%

<Main products>

Suglat [Family]	7.1	18.3%	6.7	18.0%	7.8	15.8%	6.3	14.9%
Sujanu	2.8	34.9%	2.7	30.0%	3.2	23.1%	2.6	20.1%
Repatha	1.2	52.5%	1.3	73.1%	1.5	66.7%	1.2	57.2%
Linzess	1.6	12.3%	1.5	14.6%	1.8	15.3%	1.5	16.5%
BLINCYTO	1.2	12.0%	1.0	-12.0%	1.2	-6.4%	1.1	15.9%
EVENITY	6.9	96.1%	5.8	-3.0%	6.3	-9.2%	5.8	-19.7%
Smyraf	0.2	-	0.4	365.9%	0.5	392.2%	0.5	393.5%
Celecox	11.6	-11.9%	2.7	-79.5%	2.7	-78.7%	1.9	-81.1%
Geninax	0.6	-72.6%	0.5	-72.7%	0.9	-60.9%	0.5	-64.4%
Vaccines	0.0	-99.9%	2.8	49.0%	5.1	-17.9%	0.0	-135.5%
Gonax	1.6	23.2%	1.2	-3.6%	1.1	-20.2%	1.1	-0.3%
Cimzia	2.5	4.4%	2.4	6.9%	2.8	10.3%	2.3	13.2%
Bonoteo	1.1	-40.4%	1.0	-37.2%	1.0	-35.0%	0.7	-33.5%
Lipitor	2.9	-21.2%	2.6	-18.1%	2.9	-12.5%	2.2	-12.8%
Myslee	2.1	-17.3%	2.0	-15.2%	2.2	-9.3%	1.6	-11.3%
Total Rx Sales In Japanese market	76.9	-21.5%	66.2	-21.6%	76.5	-16.4%	57.0	-16.6%

- Sales of products in Japan are shown in a gross sales basis.



## (2) United States

Unit: M\$

		FY20							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		1,089	13.6%	1,126	8.6%	1,139	7.6%	1,108	8.2%
	XTANDI	583	36.5%	550	14.2%	564	15.2%	553	16.8%
	XOSPATA	33	96.4%	35	43.8%	41	48.5%	37	31.5%
	PADCEV	27	-	29	-	32	-	33	97.7%
	Myrbetriq	213	10.0%	199	0.8%	209	-1.0%	208	-4.6%
	Vesicare	4	89.6%	11	-50.5%	3	-81.4%	2	-72.5%
	Prograf	33	12.4%	28	-19.9%	27	-24.2%	23	10.0%
	MYCAMINE	24	-10.5%	22	-21.5%	18	-31.0%	19	-27.1%
	Ambisome	22	-16.3%	29	0.8%	33	11.7%	28	-6.6%
	CRESEMBA	36	-2.3%	40	14.7%	44	0.4%	39	0.8%
	Lexiscan	111	-40.1%	180	0.6%	165	-3.8%	166	5.2%
	Tarceva	3	-82.4%	2	-52.9%	2	-70.5%	-2	-141.2%

## (3) Established Markets

Unit: M€

		FY20							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		540	-11.9%	604	1.6%	636	7.4%	589	-9.4%
	XTANDI	266	-2.4%	302	10.9%	322	17.1%	318	5.2%
	XOSPATA	9	-	7	-	11	719.4%	10	52.4%
	BETMIGA	56	1.8%	62	8.5%	61	1.9%	62	2.0%
	Vesicare	11	-78.4%	13	-40.8%	14	-23.8%	13	-31.8%
	Prograf	117	-18.5%	134	-4.1%	138	-3.5%	130	-21.6%
	Omic	15	-11.8%	17	-3.6%	18	-7.1%	16	-13.3%
	MYCAMINE	13	-10.0%	11	-25.0%	11	-18.5%	9	-27.7%
	Eligard	21	-13.3%	21	-6.4%	22	-16.4%	0	-100.0%

- Established Markets: Europe, Canada, Australia

## (4) Greater China

Unit: B¥

		FY20							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		14.2	-3.4%	15.3	4.4%	14.3	-4.5%	15.5	-3.4%
	XTANDI	0.7	31.4%	1.6	219.0%	0.9	33.3%	1.7	14.4%
	BETMIGA	0.4	12.3%	0.5	79.8%	0.6	124.6%	0.6	44.9%
	Vesicare	0.2	-52.9%	0.3	-44.1%	0.3	-42.9%	0.3	-37.5%
	Prograf	7.8	1.3%	8.4	7.9%	8.6	11.6%	9.4	4.4%
	Harnal	3.7	12.6%	3.0	-15.3%	2.2	-33.6%	1.9	-34.2%
	MYCAMINE	0.5	-45.6%	0.7	-6.6%	0.6	-53.1%	0.7	-17.0%
	Eligard	0.1	16.8%	0.1	27.0%	0.1	27.1%	0.0	-52.6%
	Feburic	0.6	-2.6%	0.6	-3.2%	0.7	13.6%	0.7	9.7%

- Greater China: China, Hong Kong, Taiwan

## (5) International Markets

Unit: B¥

		FY20							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		30.2	-11.8%	26.5	-8.9%	30.9	-21.8%	23.5	-26.4%
	XTANDI	6.9	22.7%	6.4	32.3%	6.3	-8.0%	5.8	22.3%
	BETMIGA	2.0	-2.5%	2.0	-3.9%	2.3	4.1%	2.2	5.2%
	Vesicare	0.9	-14.3%	0.9	-16.5%	1.0	-8.6%	0.9	-1.6%
	Prograf	9.0	-6.0%	6.3	-7.0%	9.1	-1.4%	7.3	19.7%
	Harnal	4.2	-1.4%	3.9	-17.7%	3.5	-19.6%	3.4	-1.6%
	MYCAMINE	1.0	-31.2%	1.0	-15.0%	1.1	-24.7%	1.2	-8.0%

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

## R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

As of Apr 2021

Underlined items indicate changes from the previous announcement in Jan 2021.

### Key post-POC projects and projects to maximize their VALUE (1/2)

Therapeutic Area	Generic Name Code No. (Brand Name)	Modality / Technology	Classification	Target Disease	Phase *	Licensor **	Remarks
Oncology	enzalutamide MDV3100 (XTANDI®)	Small molecule	Androgen receptor inhibitor	Metastatic castration-sensitive prostate cancer	Europe Filed (Jul 2019) China P-III	Pfizer	
				Non-metastatic castration-sensitive prostate cancer	P-III		
	gilteritinib ASP2215 (XOSPATA®)	Small molecule	FLT3 inhibitor	Relapsed or refractory acute myeloid leukemia	China <u>Approved (Jan 2021)</u>	In-house	
				Post-chemotherapy maintenance acute myeloid leukemia	P-III		
				Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
				Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-III		
				Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
				Acute myeloid leukemia in pediatric patients	P-III		
	enfortumab vedotin ASG-22ME (PADCEV®)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Metastatic urothelial cancer, PD-1/PD-L1 inhibitor and platinum-containing chemotherapy pretreated	<u>Europe Filed (Mar 2021)</u>	In-house [Co-development with Seagen]	
				Metastatic urothelial cancer, PD-1/PD-L1 inhibitor pretreated <u>and cisplatin-ineligible</u>	<u>US Filed (Feb 2021)</u>		
				<u>Metastatic urothelial cancer, progressed after anti-cancer medication</u>	<u>Japan Filed (Mar 2021)</u>		
				Metastatic urothelial cancer, previously untreated (first line; combo with pembrolizumab)	P-III		
Muscle-invasive bladder cancer (combo with pembrolizumab)				P-III			
Other solid tumors				P-II			

## Key post-POC projects and projects to maximize their VALUE (2/2)

Therapeutic Area	Generic Name Code No. (Brand Name)	Modality / Technology	Classification	Target Disease	Phase *	Licensor **	Remarks
Oncology	zolbetuximab IMAB362	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma	P-III	In-house (Ganymed)	
				Pancreatic adenocarcinoma	P-II		
Urology and Nephrology	roxadustat ASP1517/FG-4592	Small molecule	HIF-PH inhibitor	Anemia associated with chronic kidney disease	Europe Filed (Apr 2020)	FibroGen	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.
				Chemotherapy-induced anemia	P-II		
Others	fezolinetant ESN364	Small molecule	NK3 receptor antagonist	Vasomotor symptoms associated with menopause	P-III	In-house (Ogeda)	

\* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

\*\* Compounds with "In-house" in this column include ones discovered by collaborative research.

### Updates from the previous announcement (Jan 2021):

**enzalutamide (MDV3100):** Removed the description of the approval in China in Nov 2020 for non-metastatic castration-resistant prostate cancer.

**roxadustat (ASP1517/FG-4592):** Removed the description of the approval in Japan in Nov 2020 for anemia associated with chronic kidney disease in patients not on dialysis.

**gilteritinib (ASP2215):** Obtained the approval in China in Jan 2021 for relapsed or refractory acute myeloid leukemia with a FLT3 mutation.

**enfortumab vedotin (ASG-22ME):** Filed in US in Feb 2021 for the treatment of patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/PD-L1 inhibitor and are ineligible for cisplatin. Filed in Europe in Mar 2021 for the treatment of patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/PD-L1 inhibitor and a platinum-containing chemotherapy. Filed in Japan in Mar 2021 for the treatment of patients with locally advanced or metastatic urothelial cancer who have progressed after anti-cancer medication.

Projects with Focus Area approach (1/2)

Target (Biology)	Generic Name Code No. (Brand Name)	Modality / Technology	Therapeutic Area	Classification	Target Disease	Phase *	Licensor **	Remarks
Immunology	ASP1948/PTZ-329	Antibody	Oncology	Anti-NRP1 antibody	Cancer	P-I	In-house (Potenza Therapeutics)	
	ASP1951/PTZ-522	Antibody	Oncology	GTR agonistic antibody	Cancer	P-I	In-house (Potenza Therapeutics)	
	ASP9801	Oncolytic virus	Oncology	Oncolytic virus carrying IL-7 and IL-12	Cancer	P-I	Tottori University [Discovered through collaborative research]	
	ASP7517	Cell therapy (artificial adjuvant vector cells)	Oncology	WT1 loaded artificial adjuvant vector cell	Cancer	P-I	RIKEN [Discovered through collaborative research]	
	ASP0739	Cell therapy (artificial adjuvant vector cells)	Oncology	NY-ESO-1 loaded artificial adjuvant vector cell	Cancer	P-I	RIKEN [Discovered through collaborative research]	
Regeneration	FX-322	Small molecule	Otology	Inner ear progenitor cell activator (combination of GSK-3 inhibitor and HDAC inhibitor)	Sensorineural hearing loss	P-II	Frequency Therapeutics	Astellas has rights in Ex-US markets
	ASP7317	Cell therapy	Ophthalmology	Retinal pigment epithelium cells	Geographic atrophy secondary to age-related macular degeneration, Stargardt disease	P-I	In-house (Astellas Institute for Regenerative Medicine)	
	ASP0598	Recombinant protein	Otology	Recombinant human heparin-binding epidermal growth factor-like growth factor	Chronic tympanic membrane perforation	P-I	Auration Biotech	
Mitochondria	ASP1128/MA-0217	Small molecule	Nephrology	PPAR $\delta$ modulator	Acute kidney injury	P-II	In-house (Mitobridge)	
	ASP0367/MA-0211	Small molecule	Muscle disease	PPAR $\delta$ modulator	Primary mitochondrial myopathies	P-II	In-house (Mitobridge)	
Duchenne muscular dystrophy					P-I			

**Projects with Focus Area approach (2/2)**

Target (Biology)	Generic Name Code No. (Brand Name)	Modality / Technology	Therapeutic Area	Classification	Target Disease	Phase *	Licensors **	Remarks
Genetic regulation	resamirigene bilparvovec AT132	Gene therapy (AAV-based gene therapy)	Muscle disease	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
	AT845	Gene therapy (AAV-based gene therapy)	Muscle disease	GAA gene replacement to express GAA enzyme	Pompe disease	P-I	In-house (Audentes Therapeutics)	
Others	ASP3772	Next generation vaccine (MAPS technology)	Infectious disease	Pneumococcal vaccine based on a multiple antigen-presenting system (MAPS) platform	Prevention of pneumococcal disease	P-II	Affinivax	
	ASP0892	Next generation vaccine (LAMP-vax technology)	Immunology		Peanut allergy	P-I	Immunomic Therapeutics	
	ASP2390	New generation vaccine (LAMP-vax technology)	Immunology		House dust mite-induced allergic rhinitis	P-I	Immunomic Therapeutics [Discovered through collaborative research]	

\* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

\*\* Compounds with "In-house" in this column include ones discovered by collaborative research.

## Others

Therapeutic Area	Generic Name Code No. (Brand Name)	Modality / Technology	Classification	Target Disease	Phase *	Licensor **	Remarks
Urology and Nephrology	mirabegron YM178	Small molecule	$\beta_3$ receptor agonist	Neurogenic detrusor overactivity in pediatric patients	US <u>Approved (Mar 2021)</u> Europe P-III	In-house	
				Overactive bladder in pediatric patients	Europe P-III		
Immunology	tacrolimus FK506 (Prograf <sup>®</sup> )	Small molecule	Immunosuppressant	Prevention of rejection after lung transplantation	US Filed (Dec 2020)	In-house	
	peficitinib ASP015K	Small molecule	JAK inhibitor	Rheumatoid arthritis	China P-III	In-house	
	bleseelumab ASKP1240	Antibody	Anti-CD40 monoclonal antibody	Recurrence of focal segmental glomerulosclerosis in de novo kidney transplant recipients	P-II	Kyowa Kirin	
	ASP1617	Small molecule		Systemic lupus erythematosus	P-I	In-house	
Others	isavuconazole	Small molecule	Azole antifungal	Invasive aspergillosis and mucormycosis in pediatric patients	US P-II	Basilea	
	ASP8062	Small molecule	GABA <sub>B</sub> receptor positive allosteric modulator	<u>Opioid use disorder</u>	P-II	In-house	
				Alcohol use disorder	P-I		

\* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

\*\* Compounds with "In-house" in this column include ones discovered by collaborative research.

### Update from the previous announcement (Jan 2021):

**mirabegron (YM178):** Obtained the approval in US in Mar 2021 for neurogenic detrusor overactivity in pediatric patients aged three years and older.

**ASP8062:** Entered into Phase 2 for opioid use disorder.

## Rx+ Program

As of Apr 2021

Underlined item indicates changes from the previous announcement in Jan 2021

Sphere (Business area)	Project	Concept	Status	Partner	Remarks
Chronic disease progression prevention	Smartphone application	Offer smartphone application to support exercise using wearable device to people who needs regular exercise	Under development	BANDAI NAMCO Entertainment	
	Fitness service (Fit-eNce)	Scientifically evidenced exercise programs and systems which support regular exercise	Launched in limited areas		
	BlueStar	Digital therapeutics for adults with diabetes	Under development	Welldoc	
	<u>Program for Holter analysis devices (My Holter II)</u>	<u>AI-based data analysis program for Holter electrocardiography test</u>	<u>Japan</u> <u>Certified as a medical device (Mar 2021)</u>	<u>M. Heart</u>	
Patient outcome maximization	ASP5354	Precision surgery-guide enabling identification of ureter in hysterectomy and colorectal surgery etc.	P-II		

### Update from the previous announcement (Jan 2021)

**Program for Holter analysis devices (My Holter II):** Added as a new project.